Innovo Bioanalysis

Executive Summary

Innovo Bioanalysis is a San Diego-based diagnostics company founded in 2018 that specializes in innovative mass spectrometry-based bioanalytical methods. The company focuses on identifying biomarkers for diseases with unknown mechanisms, particularly in areas of high unmet medical need. In addition to its proprietary biomarker discovery platforms, Innovo offers contract research services for bioanalysis of drugs, metabolites, and biomarkers, supporting pharmacokinetics (PK), pharmacodynamics (PD), drug metabolism (DM), and toxicokinetics (TK) studies in drug development. By combining cutting-edge mass spectrometry with deep analytical expertise, Innovo aims to accelerate the understanding of disease pathways and improve therapeutic development. While the company remains private with limited disclosed funding, its niche capabilities in bioanalysis and biomarker discovery position it to serve biopharma clients seeking reliable and innovative analytical solutions. The company's early-stage status and lack of commercial products contribute to higher uncertainty, but its service model generates recurring revenue and potential for strategic partnerships.

Upcoming Catalysts (preview)

• Q4 2026Major Pharma Partnership for Biomarker Validation30% success
• Q3 2026Launch of LC-MS/MS Service for Biologics Characterization50% success
• Q2 2027Publication of Key Study on Rare Disease Biomarker25% success